Igor Ivanov

Dr. Igor Ivanov


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2022 in Molecules
Verified
Journal Article
Open access
PDF file
DRDanila V. Reshetnikov
Danila V. Reshetnikov
IIIgor Ivanov
Igor Ivanov
DBDmitry Baev
Dmitry Baev
TRTatyana Rybalova
Tatyana Rybalova
EMEvgenii Mozhaitsev
Evgenii Mozhaitsev
Elvira ShultsElvira Shults
Elvira Shults
Xanthine derivatives have been a great area of interest for the development of potent bioactive agents. Thirty-eight methylxanthine derivatives as acetylcholinesterase inhibitors (AChE) were designed and synthesized. Suzuki–Miyaura cross-coupling reactions of 8-chlorocaffeine with aryl(hetaryl)boronic acids, the CuAAC reaction of 8-ethynylcaffeine with several azides, and the copper(I) catalyzed one-pot three-component reaction (A3-coupling) of 8-ethynylcaffeine, 1-(prop-2-ynyl)-, or 7-(prop-2-ynyl)-dimethylxanthines with formaldehyde and secondary amines were the main approaches for the synthesis of substituted methylxanthine derivatives (yield 53–96%). The bioactivity of all new compounds was evaluated by Ellman’s method, and the results showed that most of the synthesized compounds displayed good and moderate acetylcholinesterase (AChE) inhibitory activities in vitro. The structure-activity relationships were also discussed. The data revealed that compounds 53, 59, 65, 66, and 69 exhibited the most potent inhibitory activity against AChE with IC50 of 0.25, 0.552, 0.089, 0.746, and 0.121 μM, respectively. The binding conformation and simultaneous interaction modes were further clarified by molecular docking studies.

3 November 2026 in Molecules
Verified
Journal Article
Open access
PDF file
ZNZhangeldy Nurmaganbetov
Zhangeldy Nurmaganbetov
IIIgor Ivanov
Igor Ivanov
NANurkenov Oralgazy Aktaevich
Nurkenov Oralgazy Aktaevich
VSVictor A. Savelyev
Victor A. Savelyev
Andrei KhlebnikovAndrei Khlebnikov
Andrei Khlebnikov
Elvira ShultsElvira Shults
Elvira Shults
Plant alkaloids have been of great interest in drug development research. Alkaloid lupinine is of great interest because of its availability and biological activity. While several lupinine derivatives have been identified with specific biological activities, the ongoing challenge lies in the design and synthesis of novel derivatives with high specificity for additional pharmacological targets. This paper describes the synthesis of lupinine derivatives as acetylcholinesterase (AChE) inhibitors. Two approaches were proposed and implemented for the synthesis of new compounds (yields 71–90%): the CuAAC reaction of lupinyl azide with a series of prop-2-ynyl- and ethynyl-substituted alkaloid derivatives, and a copper-catalyzed one-pot three-component reaction (A3-coupling) involving 1-((prop-2-ynyloxy)methyl)octahydro-1H-quinolizine, formaldehyde, and secondary amines. The biological activity of the new compounds was evaluated using the Ellman method; the results showed that most of the synthesized substances demonstrated good or moderate inhibitory activity against acetylcholinesterase in vitro. Hybrid compounds containing lupinine and xanthine fragments (theophylline, caffeine) 11, 12, or colchicine 15, as well as the bis-lupinyl derivative 16, exhibited the highest inhibitory activity against AChE with IC50 values of 0.47, 0.035, 1.3, and 1.4 μM, respectively. The binding conformation and simultaneous interaction modes were further clarified by molecular docking studies.